This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Johnson, S. B. Articles by Thomas, C. R. Search for Related Content PubMed PubMed Citation Articles by Johnson, S. B. Articles by Thomas, C. R., Jr.

Thymoma: Update for the New Millenium

^a Division of Cardiothoracic Surgery, Department of Surgery; ^b Department of Medical Oncology, Academic Hospital, Vrije Universiteit, Amsterdam, The Netherlands; ^c Department of Radiation Oncology, University of Texas Health Science Center, San Antonio Cancer Institute, San Antonio, Texas, USA

Correspondence: Charles Thomas, Jr., M.D., Department of Radiation Oncology, UTHSCSA, Mail Code 7800, 7703 Floyd Curl Drive, San Antonio, Texas 78229-3900, USA. Telephone: 210-616-5648; Fax: 210-949-5085; e-mail: cthomas{at}saci.org www.cancerdata.com

Thymomas are relatively common tumors of the anterior superior mediastinum. They are usually relatively slowly growing tumors and their prognosis depends on the macroscopic and microscopic invasion of surrounding tissues. Surgery is the mainstay treatment of thymomas, and complete resection represents one of the most important prognostic factors in this disease. Other important prognostic indicators include the tumor stage and size and the presence of symptoms. Postoperative radiotherapy is indicated in tumors with invasion of surrounding tissues, even if resection was radical, since it improves local control and survival. Cytotoxic chemotherapy has been employed in several relatively small phase II studies and in advanced disease has been demonstrated to produce a 50%-80% objective response rate. Neoadjuvant cytotoxic chemotherapy and/or external beam radiotherapy has been used with some success in patients with tumors which are not readily resectable. Novel antiproliferative systemic agents, with both cytotoxic and cytostatic mechanisms of action, are being tested in ongoing prospective clinical trials.

Key Words. Thymoma • Myasthenia gravis • Tumor stage

This article has been cited by other articles:

				B. Yelken, S. Namli, N. Gorgulu, and T. Ecder Focal segmental glomerulosclerosis associated with Good's syndrome NDT Plus, February 1, 2008; 1(1): 26 - 27. [Full Text] [PDF]

				M. Lucchi, M. C. Ambrogi, L. Duranti, F. Basolo, G. Fontanini, C. A. Angeletti, and A. Mussi Advanced Stage Thymomas and Thymic Carcinomas: Results of Multimodality Treatments Ann. Thorac. Surg., June 1, 2005; 79(6): 1840 - 1844. [Abstract] [Full Text] [PDF]

				P Kelleher and S A Misbah What is Good's syndrome? Immunological abnormalities in patients with thymoma J. Clin. Pathol., January 1, 2003; 56(1): 12 - 16. [Full Text] [PDF]

				A. Evoli, C. Minisci, C. Di Schino, F. Marsili, C. Punzi, A. P. Batocchi, P. A. Tonali, G. B. Doglietto, P. Granone, L. Trodella, et al. Thymoma in patients with MG: Characteristics and long-term outcome Neurology, December 24, 2002; 59(12): 1844 - 1850. [Abstract] [Full Text] [PDF]

				S. Umemura, Y. Segawa, K. Fujiwara, I. Takata, N. Seki, Y. Tokuda, K. Eguchi, and K. Mandai A Case of Recurrent Metastatic Thymoma Showing a Marked Response to Paclitaxel Monotherapy Jpn. J. Clin. Oncol., July 1, 2002; 32(7): 262 - 265. [Abstract] [Full Text] [PDF]